ESTRO 2024 - Abstract Book

S2425

Clinical - Urology

ESTRO 2024

Number of metastatic lesions 1

19 (55.9) 11 (32.3) 4 (11.8)

2 3

Conclusion:

Our findings suggest that hypermetabolic CTC in OMPC patients undergoing SBRT could be detected and used as prognostic biomarker for DPFS. By combining CTC level and the number of oligometastases, patients with an indolent oligometastatic disease, potentially well-managed by SBRT alone, could be identified. A validation of our findings in an external dataset is ongoing in a multicenter prospective trial.

Keywords: oligometastatic, prostate, circulating tumor cells

References:

1. Deek MP, Van der Eecken K, Sutera P, et al. Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials. JCO. 2022;40:3377 – 3382.

2. Colosini A, Bernardi S, Foroni C, et al. Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study. Biomedicines. 2022;10:1321.

3. Stelcer E, Konkol M, Gł ȩ boka A, et al. Liquid Biopsy in Oligometastatic Prostate Cancer- A Biologist’s Point of View. Front Oncol. 2019;9:775.